Abstract:Objectives Many cancer biomarkers such as the circulating tumor cells/microemboli (CTCs/CTM) have been reported significant associations with clinical outcomes. However, different biomarkers have different sensitivities and specificities for cancer types and cohort patients, and synergistic effects between certain biomarkers have also been observed, leading to the inaccurate, fluctuating, and even controversial results when multiple biomarkers are analyzed together. In this paper, a novel combinational index, P-score, was developed for monitoring and predicting the disease condition of lung cancer patients during follow-up visits. Materials and Methods There were totally 13 return patients with 54 blood samples involved in this study to examine the number of CTC and CTM. Information from one group of 7 patients including 27 blood samples with published clinical data was employed to develop while those from another group of 4 patients containing 14 blood samples with unpublished clinical data were used to validate the P score in prediction. Enumerations were based on immunofluorescent staining images. Distributions of CTC/CTM and their frequencies in stratified patients were carefully examined and analyzed the ROC curve and AUC value to develop the P score and P score-based prediction model. Results and Conclusion We found that the predictive power of P-score was not only comparable to the traditional cancer marker, in comparison with individual CTC/CTM, more false positives could be corrected by using P-score, thereby to improve the accuracy of analysis. From our preliminary validation tests, the prognosis and disease progression monitored longitudinally by P-score were further confirmed by clinical outcome data from physicians and its sensitivity was even better than those from individual biomarkers. We believe that this novel combinational indicator could be a promising tool to interpret clinical outcomes more accurately from multiple factors, particularly useful for the early prognosis and longitudinal monitoring in cancer patient management.

Identifying the critical state of cancers by single-sample Markov flow entropy.

Identifying the Critical States and Dynamic Network Biomarkers of Cancers Based on Network Entropy

Multi-omics with Dynamic Network Biomarker Algorithm Prefigures Organ-Specific Metastasis of Lung Adenocarcinoma

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Single-Sample Node Entropy for Molecular Transition in Pre-deterioration Stage of Cancer.

Single-sample landscape entropy reveals the imminent phase transition during disease progression

Identifying the critical states of complex diseases by the dynamic change of multivariate distribution

SPNE: Sample-Perturbed Network Entropy for Revealing Critical States of Complex Biological Systems

Identifying Critical State of Complex Diseases by Single-Sample-Based Hidden Markov Model

Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes

A novel workflow for cancer blood biomarker identification

Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data

Development and Validation of a Novel Combinational Index of Liquid Biopsy Biomarker for Longitudinal Lung Cancer Patient Management

Identification of Monotonically Differentially Expressed Genes across Pathologic Stages for Cancers

Identifying Critical State of Complex Diseases by Single-Sample Kullback–Leibler Divergence

Uncovering the Pre-Deterioration State during Disease Progression Based on Sample-Specific Causality Network Entropy (SCNE)

Identification of Prognostic and Heterogeneous Breast Cancer Biomarkers Based on Fusion Network and Multiple Scoring Strategies.

A three-stage approach to identify biomarker signatures for cancer genetic data with survival endpoints

Identifications of the potential in-silico biomarkers in lung cancer tissue microbiomes

Identification of Gene Signatures and Expression Patterns During Epithelial-to-Mesenchymal Transition From Single-Cell Expression Atlas